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Diagnosis and treatment of venous lymphedema
Seshadri Raju, MD, James Brooke Furrh, IV, BS, and Peter Neglén, MD, PhD, Flowood, Miss
Background: Chronic venous disease (CVD) is a common cause of secondary lymphedema. Venous lymphedema is
sometimes misdiagnosed as primary lymphedema and does not receive optimal treatment. We have routinely used
intravascular ultrasound (IVUS) imaging in all cases of limb swelling. The aim of this study is to show that (1) routine
use of IVUS can detect venous obstruction missed by traditional venous testing, and (2) iliac-caval venous stenting can
yield satisfactory clinical relief and can sometimes reverse abnormal lymphangiographic findings.
Methods: The study comprised CVD patients who underwent iliac vein stenting. Lymphangiography was abnormal in 72
of 443 CEAP C3 limbs, with leg swelling as the primary complaint (abnormal lymphangiography group). Clinical features
and stent outcome were compared with a control group of 205 of 443 with normal lymphangiography (normal
lymphangiographic group).
Results: Clinical features were a poor guide to the diagnosis of lymphedema. Isotope lymphangiography was not helpful
in differentiating primary from secondary lymphedema. Venography had 61% sensitivity to the diagnosis of venous
obstruction. IVUS had a sensitivity of 88% for significant (>50% area stenosis) venous obstruction. At 40 months,
cumulative secondary stent patency was similar for the abnormal (100%) and normal lymphangiographic (95%) groups.
Swelling improved significantly after stent placement in the abnormal lymphangiographic group (mean [standard
deviation] swelling grade improvement 0.8  1.1) but was less (P < .004) than in the control group (1.4  1.3).
Complete swelling relief was 16% and 44% (P< .001) and partial improvement (>1 grade of swelling) was 45% and 66%
(P < .01) in the abnormal and normal lymphangiographic groups, respectively. Associated pain was present in 50% and
36% of the swollen limbs in the abnormal and normal lymphangiographic groups. Pain relief (>3 visual analog scale) at
40 months was 87% and 83%, respectively (P  .3), with 65% and 71%, experiencing complete pain relief. Quality of life
criteria improved after stent placement in both groups but to a better extent in the normal lymphangiographic group.
Abnormal lymphangiography improved or normalized in 9 of 36 (25%) of those tested after stent correction.
Conclusions: Prevailing practice patterns and diagnostic deficiencies probably result in the misdiagnosis of many cases of
venous lymphedema as “primary” lymphedema. IVUS is recommended to rule out venous obstruction as the associated
or initiating cause of lymphedema. Iliac venous stenting to correct the obstruction has excellent long-term patency and
good clinical outcome, although results are not as good as in those with normal lymphatic function. (J Vasc Surg 2012;
55:141-9.)
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sLymphedema is classified into primary and secondary
types. Primary lymphatic dysfunction is of congenital or idio-
pathic origin. Secondary lymphedema is from damage to
lymphatic structures from parasites, surgery, radiation, or in-
fection, commonly cellulitis. Secondary lymphedema from
Filariasis has a much higher prevalence in tropical countries
than the primary variety. Surgical or radiation damage to
regional lymph nodes is a major source of secondary
lymphedema inWestern populations. When such a secondary
cause is excluded, the lower limb swelling in a large group of
patients is often assumed to be primary in nature.
In patients with advanced chronic venous disease
(CVD), 20% to 30%will have associated lymphatic dysfunc-
tion, presumably due to secondary damage from overload
or recurrent cellulitis.1-3 The term phlebolymphedema
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doi:10.1016/j.jvs.2011.07.078s variably used to designate this form of lymphedema
f venous origin.4 The very high incidence of CVD in
he general population would suggest that secondary
ymphedema from this cause has a high relative prevalence,
robably several times more than the primary variety. Yet,
his is not common knowledge among primary care physi-
ians, and limb swelling is often labeled as “primary
ymphedema” on clinical grounds alone, which are unreli-
ble (Figs 1 and 2) because they are not exclusive to primary
ymphedema.
Nucleotide lymphangiography is variably performed
or diagnosis, but this test by itself cannot reliably differen-
iate primary from secondary lymphedema3,5 because de-
ayed or absent node visualization can occur in either case.
enous investigations are seldom done. Compounding the
roblem is that duplex imaging, the main venous diagnos-
ic modality, is insensitive to iliac vein lesions with routine
echnique, and venography, which is used less often, will
iss as many as 50% of correctable venous pathology (Fig
).6-8 Intravascular ultrasound (IVUS) imaging is more
efinitive9 but has not yet been adopted widely, even in
pecialized venous centers. As a result of these prevailing
ractice patterns, a large number of patients with correct-
ble venous lesions are inappropriately consigned to life-
ong compression and are often referred to physiotherapists
pecializing in manual drainage and decongestive ther-
py.4,10
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January 2012142 Raju et alWe have routinely used IVUS imaging in all patients
presenting with leg swelling, regardless of positive or neg-
ative preoperative test results for venous obstruction or
lymphatic function. The diagnostic yield of IVUS-positive
iliac-caval-femoral obstructions is very high in these pa-
tients.6 We present our clinical experience with 72
lymphedematous limbs with abnormal lymphangiograms
and associated venous obstruction identified by IVUS im-
aging. All were treatedwith iliac vein stents, and the results are
detailed in comparison with 205 similarly treated swollen
obstructed limbs that had normal preoperative lymph-
angiograms. The objective of this study is to show that
routine use of IVUS imaging can substantially increase the
Fig 1. Swelling in the dorsum foot, squaring of toes, and
of lymphedema. In our experience, these may also be pre
lymphedema (see text). Left, This patient was diagnosed
for several decades with compression, which was ineffect
Transfemoral venography showed postthrombotic iliac v
Fig 2. This patient had onset of leg swelling from early
was normal on the left. Venogram showed bilateral iliac ve
iliac vein stenosis. Note the normal caliber of the femoradiagnostic yield of correctible lesions in lymphedematous wimbs that might be otherwise labeled as suffering from
rimary lymphedema with uncorrectable underlying pa-
hology and that stent correction of the detected lesions
an yield substantial clinical relief.
ATIENTS AND METHODS
During a 13-year period (1997 to 2010), 1739 patients
ith symptoms suggestive of CVD underwent iliac-
aval-femoral venous stenting after investigations. Iso-
ope lymphangiography was performed in 819 of these
hen primary or secondary complaints of limb swelling or
ellulitis were present. The result was abnormal in 201 of
19 patients (26%). In many of these 819 limbs, swelling
mer sign are widely considered “classic” clinical features
long-standing venous swelling and are not exclusive to
ving “lymphedema” on clinical grounds and was treated
iddle, Isotope lymphangiography was normal. Right,
enosis (left venogram is shown).
scence. Lymphatic delay was noted on the right side but
noses. Right limb venogram is shownwith severe diffuse
.Stem
sent in
as ha
ive. Madole
in steas transient or a secondary feature associated with skin
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Volume 55, Number 1 Raju et al 143changes (eg, lipodermatosclerosis) or ulceration that would
have complicated analysis for purposes of this study. To
focus on swelling and swelling-related outcome, current
analysis pertains only to CEAP C3 limbs in this group (443
of 819) with swelling as the main clinical feature. The test
group (abnormal lymphangiographic group) consisted of
72 of 443 (16%) of these limbs in 69 patients where
preoperative lymphangiography results were abnormal.
The controls were 205 limbs in the same CEAP C3 subset
with leg swelling in whom the preoperative isotope lymph-
angiography result was normal (normal lymphangiographic
group) and that had adequate follow-up data for outcome
comparisons. Associated limb pain was an additional clini-
cal feature in both test and control groups.
The clinical and investigative evaluations of patients
with suspected CVD have been described in detail previ-
ously.11 Only those relevant to the present report are
included.
Venography. Venography was by the transfemoral
route, except when it was precluded by clinical or technical
factors, such as renal failure, international normalized ratio
2, massive obesity, or access failure.
Isotope lymphangiography. An injection of 0.6MCI
of technetium 99M sulfur colloid was placed subcutane-
ously between first and second toe web space, and the
progress monitored at 10, 20, and 40 minutes, or longer
(up to 2 hours), while exercising the limb, for evidence of
node visualization. Pooling and dermal backflow were
noted when present. Assessment was based on time-related
node visualization: normal when seen by 20 minutes, de-
layed when longer, and absent when imaging at 2 hours was
Fig 3. Venography is poorly sensitive to iliac vein obst
tight stenosis is present, as shown by the IVUS image.
Normal value in adults is 175 mm2. A 75% stenosis canegative. tTriple-dose lymphangiography. An injection of 1.8
CI of isotope colloid was placed into the web space
ecause a relatively large fluid depot might have diluted the
sotope retarding visualization. This technique was used in
1 CVD limbs (all CEAP classes) whose normal-dose lym-
hangiogram showed delayed or absent node visualization.
ormalization with the triple-dose technique was found in
0 limbs (14%; Fig 4), and 16 limbs were CEAP C3 and are
ncluded in the current series.
IVUS assessment and stent placement. Only pa-
ients in whom compression or conservative therapy had
ailed were considered. The stenting technique has been
escribed in detail elsewhere.12,13 IVUS (6F) was routinely
sed for diagnosis and stent correction of obstructive le-
ions. Wallstents (Boston Scientific, Watertown, Mass)
ere exclusively used. Aspirin was routinely used for stent
aintenance. Warfarin therapy was reserved for patients
ith thrombophilia, recurrent thrombosis, or previous un-
rovoked thrombosis. The compression regimen in place at
he time of intervention was continued after stent place-
ent.
Reinterventions to correct stent malfunction were re-
uired in 17 of 72 limbs (24%) in the abnormal lymphan-
iography group and in 53 of 205 limbs (26%) in the
ontrol group.14 Stent malfunction was mostly due to
n-stent restenosis or stent compression, sometimes associ-
ted with poor stent inflow/outflow as a result of new or
reviously missed lesions adjacent to the stent. Reinterven-
ions included four successfully lysed stent occlusions in the
ontrol group. Reinterventional outcome is integrated into
n. Left, A venogram appears unremarkable. Right, A
sured lumen area by IVUS planimetry was 44.3 mm2.
efore be calculated to be present.ructio
Meahe results as reported for both groups.
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January 2012144 Raju et alOutcome assessment. Patients were seen in follow-up
by one of the authors (S.R. or P.N.) at 6 weeks, at 3, 6, and
12 months, and at yearly intervals thereafter. Pain assess-
ment was by visual analog scale (VAS),15 and swelling was
assessed by subjective report of the patient (improved or
not) and by objective physical examination: grade 0, none;
grade 1, mild pitting or nonpitting but not obvious; grade
2, obvious swelling limited to the foot and ankle; grade 3,
obvious swelling involving the limb above the ankle.
The Chronic Venous Insufficiency Quality of Life
Questionnaire16,17 was used to assess quality of life, and
preoperative questionnaire results and the last assessment
available after stent placement were used for analysis. A
transfemoral venogram was obtained at 3 or 6 months for
routine assessment of the stent and as needed when stent
malfunction was suspected. Duplex assessment of the stent,
using a special technique described by Labropoulos et al,18
was performed at shorter intervals. All clinical and investi-
gative results were entered into a time-stamped electronic
medical record (EMR) system prospectively at the time of
encounter and analyzed retrospectively. Because existing
data were being presented in aggregate anonymous fash-
ion, Investigational Review Board approval was not re-
quired for this study.
Statistical analysis. Individual data are given as me-
dian with range or mean  standard deviation, unless
otherwise indicated. Continuous variables were analyzed:
Wilcoxon rank test for paired data, Mann-Whitney test for
unpaired data, and Fisher exact test for categoric variables.
Primary, assisted primary (patency after preemptive inter-
vention), and secondary patency (patency after intervention
for occlusion) rates, as defined by the reporting standards of
the International Society for Cardiovascular Surgery/Soci-
Fig 4. In some cases, lymphatic delay (left) with standar
colloid is injected (right).ety for Vascular Surgery19 were calculated using survival flnalysis with the Kaplan-Meier method. Cumulative sur-
ival analysis was also used to analyze and compare recur-
ence of pain, swelling, and ulcer after the treatment. The
og-rank test was used to compare cumulative curves.
raphPad Prism 5.03 software (GraphPad Software, San
iego, Calif) was used for analysis. Results are reported
sing P values and effect or odds ratio for continuous and
ategoric variables, respectively. A value of P  .05 was
onsidered significant. The counts for individual variables
ay vary slightly from the aggregate number of limbs
ecause of missing data in some fields and are shown in
ontext.
ESULTS
Demographics and relevant clinical features of abnor-
al lymphangiography and control groups are reported in
able I. The abnormal lymphangiographic group was sig-
ificantly younger by about a decade and had more women
nd slightly greater proportion of primary cases than the
ormal lymphangiographic group. There was no significant
ifference in other categories. Familial history of swelling,
arly or late age of onset, incidence of bilateral limb swell-
ng, associated limb pain (or its absence), and pain severity
ere similar in both groups, meaning that these are not
eliable discriminatory features to diagnose lymphedema.
The breakdown of physical swelling severity is reported
n Table II. The median swelling grade, grade distribution,
nd incidence of grade 3 swelling were no different be-
ween the two groups.
In the 72 limbs with abnormal lymphangiograms, node
isualization was absent in 16 (22%) and delayed in 56
78%). Isotope pooling in the lower leg and dermal back-
nique will normalize if triple dose of the isotope-taggedd techow was present in 14 limbs (19%).
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Volume 55, Number 1 Raju et al 145Stented lesions were nonocclusive stenoses, except
three limbs in the abnormal lymphangiographic group and
nine in the control group that were recanalizations of
chronic total occlusions. The disease was typically segmen-
tal in postthrombotic disease and subsegmental in “pri-
mary” pathology.6 The common iliac vein was stented in all
limbs except one in the control group, where the stent was
restricted to the external iliac vein and the common femoral
vein. In most cases, the stent in the common iliac vein was
extended caudad into the external iliac vein or frequently
into the common femoral vein because of involvement of
postthrombotic disease or the presence of distal “primary”
lesions at the common-external iliac junction or the ingui-
nal ligament. The lower end of the stent was extended into
the external iliac vein in 10 limbs (14%) in the abnormal
lymphangiographic group and in 12 limbs (6%) in the
control group, and into the common femoral vein in 59
limbs (83%) of the abnormal lymphangiographic group and
in 156 limbs (76%) of the control group. The upper end of
Table I. Demographics of normal and abnormal
lymphangiography groups
Variablea
Lymphangiography result
P
Abnormal Normal
(n  72) (n  205)
Body mass index 33 (17-53) 33 (18-57) .887
Age 48 (18-86) 57 (17-91) .001b
Male:female 1:8 1:3 .001b
Primary:postthrombotic 4:3 1:1 .001b
Age at onset, years
20, % 8 4 .245
60, % 29 29 .499
Family history of
swelling, %
1 3 .142
Duration of symptoms,
years
6 (0-54) 3 (0-58) .368
Bilateral limb
swelling, %
44 43 .891
Associated limb pain, % 50 36 .061
Pain level (visual analog
scale)
6.23  1.93 6.10  1.67 .655
aContinuous data are shown as median (range) or as mean  standard
deviation.
bStatistically significant.
Table II. Swelling severity in limbs with abnormal and
normal lymphangiography
Swelling grade
Lymphangiography result
P
Abnormal Normal
(n  72) (n  194)
Grade 1, No. (%) 7 (10) 25 (13) .533
Grade 2, No. (%) 10 (14) 31 (16) .845
Grade 3, No. (%) 55 (76) 138 (71) .442
Median (range) 3 (1-3) 3 (1-3) .651the stent was routinely extended 3 to 5 cm into the inferior nena cava for technical reasons.11,12 The stent stack was
xtended even higher into the vena cava because of its
nvolvement in primary6 or postthrombotic disease: in 7
imbs (10%) in the abnormal lymphangiographic group and
n 25 limbs (12%) of the control group.
At 30 days there were no deaths, and procedural mor-
idity was minor, consistingmostly of back pain in25% of
atients. No patients required readmission. Access site he-
atoma/seroma occurred in 1.5%. Stent embolization to
he upper vena cava occurred intraoperatively (none later)
n 2%; all were successfully repositioned/retrieved during
he procedure. There was no perioperative hemorrhage
equiring transfusions. Postoperative deep venous throm-
osis (30 days) occurred in one limb (1.4%) of the
bnormal lymphangiographic group and in seven limbs
3.5%) of the control group combined with pulmonary
mbolus in one instance. All affected limbs, except one limb
ith calf vein thrombus in the control group, were success-
ully managed by thrombolysis.
Venography was poorly sensitive to the presence of
bstruction in the lymphedematous group. Preoperative
enography in 57 limbs was suggestive of an iliac vein lesion
n 61%, including collaterals being present in 26%. Intraop-
ratively, obstructive lesions were detectable by IVUS in 63
f 68 limbs in the abnormal lymphangiographic group and
n 165 of 191 limbs in the normal lymphangiographic
roup (overall 228 of 259) yielding a diagnostic sensitivity
f 88% for IVUS. Although impervious to IVUS, stentable
esions were shown to be present in 31 of 259 (12%) of the
imbs by balloon waisting detected on routine balloon
izing maneuvers. All IVUS missed lesions were discrete
membranous?) at or near the hypogastric vein orifice,
hich seemed to obscure their presence. The mean area of
tenosis on IVUS planimetry (missed lesions were scored as
% stenosis) was 70%  20%.
Mean follow-up was 27 33 months for the abnormal
ymphangiographic group and 18  21 months for the
ig 5. Cumulative stent patency in abnormal lymphangiographic
roup. Assisted primary and secondary patency curves were the
ame. The error bars show the standard deviation.ormal lymphangiographic group. Cumulative primary,
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January 2012146 Raju et alprimary assisted, and secondary stent patency rates at 40
months were 51%, 100%, and 100% in the lymphedematous
group (Fig 5) and 51%, 95%, and 95% in the control group
(curves not shown). These curves did not differ between
the two groups (P  .2775, log-rank Mantel-Cox).
Swelling improvement after iliac vein stenting is re-
ported in Table III and Fig 6. Although objective swelling
improved after iliac vein stenting, the degree of partial or
complete improvement was less in the abnormal lymphan-
giographic group than in the control group.
Most patients in both groups were noncompliant with
compression stockings, in line with previous observa-
tions.19 At follow-up, only 25 of 72 (35%) in the abnormal
lymphangiographic group and 57 of 205 (28%) in the
control group were wearing compression stockings.
Poststent lymphangiograms to assess improvement
were available in 36 limbs with abnormal preoperative
lymphangiography. Functional normalization (Fig 7) was
seen in 7 limbs (19%), with improvement in an additional 2
Table III. Swelling outcome after stent placement in
limbs with abnormal and normal lymphangiography
Swelling variablea
Lymphangiography
result
P
Abnormal Normal
(n  51) (n  194)
Swelling grade
Pre-stent 2.7  0.6 2.6  0.7 .069
Post-stent 2.0  1.2 1.2  1.3 .001b
Swelling grade improvement 0.8  1.1 1.4  1.3 .004b
Complete swelling relief 8 (16) 86 (44) .001b
Relief grade 23 (45) 127 (66) .010b
aContinuous data are presented as mean  standard deviation; categoric
data as number (%).
bStatistically significant.
Fig 6. Swelling relief (cumulative) is shown after stent placement
in lymphedematous limbs. Separate curves are shown for subjective
relief, as reported by the patient, and for objective relief by exam-
ination. The difference in the curves may partly be due to metrics
(see text). The error bars show the standard deviation.limbs (6%), for a total of 25%. cThere was significant pain relief (P  .001) in both
roups after iliac vein stenting; cumulative pain relief was
imilar in the two groups (curves not shown; P  .8,
og-rank Mantel-Cox). There was pain relief of at least 3
oints in the 10-point VAS scale in 85% and 91% of patients
n the abnormal and normal lymphangiographic groups,
espectively. Mean VAS pain level declined from 6.3  1.9
o 2.0  3.3 in the abnormal lymphangiographic group
nd from 6.1 1.7 to 0.6 1.7 in the control group (P
4). There was complete pain relief in 69% and 86% of
atients in the abnormal and normal lymphangiographic
roups, respectively (P  .06).
Quality of life data comparisons between the test and
ontrol groups are reported in Table IV. The sample size in
he abnormal lymphangiographic group is small. Activity
mproved significantly in the abnormal lymphangiographic
roup. Pain, activity, and sleep parameters improved in the
ormal lymphangiographic group but not social or morale
etrics. Overall scores showed an improving trend but did
ot reach statistical significance (P  .08) in the abnormal
ymphangiographic group. Overall scores were significantly
mproved (P  .001) in the normal lymphangiographic
roup.
ISCUSSION
Limb swelling completely cleared in one in six patients
ith abnormal lymphatic function in this series, and about
alf had objective improvement in swelling. Pain relief was
ore substantial and more widespread. Although these
linical benefits clearly warrant stent treatment, the swelling
utcome was less than in the control series with normal
ymphatic function; quality of life criteria, although im-
roved after stent placement, were less than in the control
eries. Nonreversible ongoing lymphatic dysfunction is the
ikely cause for these differences. As a clinical impression,
welling extent and severity was greater in the abnormal
ymphatic group, although this was not possible to docu-
ent (see below).
Subjective improvement in limb swelling was reported
y two-thirds of patients with abnormal lymphangiogra-
hy, but objective improvement could be confirmed in only
ess than half the patients. A placebo effect is an obvious
xplanation. But there are metrics problems with current
rading of swelling severity, which lacks adequate resolu-
ion to measure improvement within the grade. In massive
rade 3 swelling (Figs 1 and 2), improvement may be
ubstantial, yet still remain grade 3, thus not allowing
ocumentation of objective improvement. For example,
welling involving the thigh and legs will be classified as
rade 3, even after swelling recedes to below the knee. Such
mprovement may be significant enough to allow better
obility, climb stairs, or abandon a wheel chair existence.
welling is better tolerated if associated pain is relieved.
The grading system implies that there is a stepwise
rogression of swelling from foot and ankle (grade 2) to
nvolve the rest of the lower limb (grade 3). In our clinical
xperience, the foot, leg, and thigh may act as separate
ompartments for swelling in some patients. After iliac vein
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Volume 55, Number 1 Raju et al 147stenting, one or the other may resolve with residual swell-
ing in the other compartment. Foot swelling is relatively
poorly tolerated compared with the ankle and the leg above
in some patients, particularly women, where the ability to
wear proper shoes is a significant consideration. Foot swell-
ing may resolve with clinical benefit even though residual
swelling above persists in obese and lipedematous patients.
Residual swelling in the plantar region is annoying to many
patients, yielding an uncomfortable sensation of walking on
Fig 7. Left, Lymphographic nonvisualization of inguin
After iliac vein stent placement, nodes promptly visualize
Table IV. Chronic Venous Disease Quality of Life
Questionnaire (CIVIQ) outcome in limbs with abnormal
and normal lymphangiography
CIVIQ categorya
Preoperative Postoperative
P
Median
(range)
Median
(range)
Lymphangiography
result
Abnormal (n  25)b
Pain intensity 3 (1-5) 2 (1-5) .118
Activity limits 3 (1-5) 2 (1-5) .007c
Sleep problems 3 (1-5) 2 (1-5) .174
Social 2 (1-5) 3 (1-5) .096
Morale 3 (1-5) 2 (1-5) .393
Total 52 (20-100) 44 (20-100) .078
Normal (n  67)b
Pain intensity 3 (1-5) 2 (1-5) .001c
Activity limits 3 (2-5) 2 (1-5) .001c
Sleep problems 3 (2-5) 2 (1-5) .004c
Social 3 (2-5) 2 (1-5) .096
Morale 3 (1-5) 2 (1-5) .227
Total 60 (44-100) 44 (28-96) .001c
aScores for outcomes for each category range from 2 (best) to 5 (worst).
bData available for questionnaires before and after stent placement.
cStatistically significant.a spongy surface. lIt would seem that objective improvement in limb
welling can be reliably assessed by limb volume plethys-
ography. Plethysmographic techniques have been shown
o be accurate in the controlled setting of physiologic
aboratories. In clinical practice, tape measurements are
idely used, but single point measurements are unreliable.
easurements over multiple anatomically fixed points are
ecessary, a task that becomes even more difficult when
welling involves the entire limb, not merely below the
nee. A variety of other techniques have been described to
easure limb edema, but many have not been validated or
re too complex or expensive for routine use.20,21 A prac-
ical difficulty even with validated techniques in the clinical
etting is that extravascular fluid volume undergoes cyclical
hanges over days or weeks and intraday limb volume has a
ronounced diurnal variation. An early version of the Ve-
ous Clinical Severity Score scoring system was based (time
f day to reach maximum swelling) on this well-known
linical observation. This means that measurement has to
e done at the same time of the day for valid comparison.
Compression stockings can be helpful when properly
sed in patients when limb swelling is not massive. Patient
oncompliance with compression is notoriously high, even
n the presence of severe symptoms, and medical supervi-
ion and patient education have not resulted in better
ompliance.19 Manual drainage and decongestive therapy
re effective techniques when properly administered.22
assage techniques do not correct the basic pathology,
owever, and intensive lifelong daily compliance is neces-
ary. In venous lymphedema, it is best used in conjunction
ith correction of venous pathology.
Isotope lymphoscintigraphy has replaced the older
ontrast lymphangiographic technique because of its rela-
ive simplicity and technical ease. Magnetic resonance
des in a patient with right-sided lymphedema. Right,
20 minutes.al noymphangiography is an emerging technique but has
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Lymphangiographic assessment is based on gross visual
inspection, which may not always be reliable.5 A variety of
metric enhancements of the technique can yield more
precise information, but the methodology is rather com-
plex and unsuitable for routine use.
Visual lymphoscintigraphic assessment has not been
standardized, and a variety of parameters have been variably
used such as the number and appearance of lymphatic
channels, nodal intensity, and number of nodes visual-
ized.3,5,10 Time for node visualization is the most widely
usedmetric, as in the current study, although different time
scales have been used by different authors. Stagnation of
the isotope in tissues and dermal backflow are also univer-
sally recognized indicators of impaired function. Delayed
or absent node visualization may be due to transport failure
at one or more locations in the lymphatic pathways: mi-
crolymphatics near the capillaries, larger precollectors, and
the collectors themselves arborizing with regional lymph
nodes. Transport failure in venous disease is at the level of
microlymphatics. The collectors and nodes themselves re-
tain their functional competence,5,23 except when second-
ary damage from age (decreased function),5 cellulitis, or
the hypertrophic reaction of collector vessels to lymph stasis
is superimposed. The cause of microlymphatic damage is
presumed to be due to overload use or involvement in the
microvascular inflammatory cascade that besets CVD.
Current and previous work24 with a more diffuse
patient population (all CEAP classes were included) show
that restoration to normal lymphatic function is possible if
the underlying CVD pathology is corrected. Early correc-
tion may be important because lymph stasis itself perpetu-
ates lymphatic damage, which may become irreversible at
some stage. The current series likely included limbs with
irreversible primary lymphedema with coincident venous
obstruction. Because venous obstruction is ubiquitous25 in
the general population, coincidence is to be expected. In
either case, it would seem important to identify and correct
venous obstruction as a contributory cause to leg swelling
and lymphatic damage.
CONCLUSIONS
CVD is a common disease. That a third or more pa-
tients with CVD1,2 will have lymphatic dysfunction by
isotope lymphangiography suggests that this form of sec-
ondary lymphedema is probably several times more com-
mon than the primary variety. Venous pathology therefore
should be ruled out before labeling lymphedema as of
primary cause. Clinical features, isotope lymphangiogra-
phy, routine duplex imaging, and venography cannot reli-
ably rule out a venous cause. New diagnostic modalities,
such as high-resolution imaging and enhanced duplex tech-
niques,18 are in evolution, but their diagnostic sensitivity
has not been established. We suggest that IVUS be rou-
tinely used before referring patients to conservative therapy
on the premise that the disease is primary lymphedema.UTHOR CONTRIBUTIONS
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